← Leaderboards
Jennifer D Wu
University Of Washington
$10,794,755
Attributed
$14,985,730
Total exposure
12
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,985,730 · 12
By mechanism
R01$10,339,882 · 6
P50$1,698,286 · 2
R44$1,499,979 · 1
K01$698,145 · 1
R43$399,444 · 1
R41$349,994 · 1
Top collaborators
- Sarki A. Abdulkadir5 shared
- Richard R Drake5 shared
- Jeffrey A Sosman3 shared
- Grant H Risdon2 shared
- Shay Bracha1 shared
- Robert H Pierce1 shared
- Seth M Pollack1 shared
Most similar at University Of Washington
Same institution · by research overlap
- Matt Kaeberlein$21,041,861
- Kate Elizabeth Creevy$6,518,683
- Stephanie McGrath$1,908,022
- May J Reed$5,889,471
Others in their field
Top investigators on “Tumor”
- David Heimbrook · Leidos Biomedical Research, Inc.$636,492,067
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Gregory H Reaman · National Childhood Cancer Foundation$208,276,509
- Richard K. Wilson · Washington University$203,917,615
- Norman Wolmark · Nsabp Foundation, Inc.$177,323,696
- Ronald T Mitsuyasu · University Of California Los Angeles$138,361,819
Research focus
TumorLigandsAntibodiesMediatingCancer PatientSerumBaseReceptorImmuneNeoplasm MetastasisImpairmentSurfaceTranslatingClinical TrialsAntigensSignal TransductionCd8-Positive T-LymphocytesProstateProstatic NeoplasmsNeoplastic CellCell SurfaceT-LymphocyteFutureCells
Grant awards (40)
Targeting MIC to Augment Adoptive NK Therapy Using the Canine Soft Tissue Sarcoma Model$672,844
R01 · FY2025 · CA
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity$663,989
R01 · FY2025 · CA · contact PI
Feasibility study of a novel NK and CD8 T cells stimulating agent$399,444
R43 · FY2025 · CA
Project 2: Re-directing the Sensitivity of Metastatic Castration-Resistant Prostate Cancer to Immunotherapy$360,000
P50 · FY2025 · CA · contact PI
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity$630,790
R01 · FY2024 · CA · contact PI
Project 2: Re-directing the Sensitivity of Metastatic Castration-Resistant Prostate Cancer to Immunotherapy$344,686
P50 · FY2024 · CA · contact PI
Pathway-guided treatment of immune checkpoint inhibitor therapy-induced colon toxicity$663,989
R01 · FY2023 · CA · contact PI
Project 2: Re-directing the Sensitivity of Metastatic Castration-Resistant Prostate Cancer to Immunotherapy$334,800
P50 · FY2023 · CA · contact PI
Tumor immune and glycan biomarkers for progressive prostate cancer$552,871
R01 · FY2022 · CA · contact PI
Project 2: Re-directing the Sensitivity of Metastatic Castration-Resistant Prostate Cancer to Immunotherapy$334,798
P50 · FY2022 · CA · contact PI
Target MIC shedding to revive anti-tumor immunity$305,456
R01 · FY2022 · CA · contact PI
Tumor immune and glycan biomarkers for progressive prostate cancer$561,790
R01 · FY2021 · CA · contact PI
Project 2: Re-directing the Sensitivity of Metastatic Castration-Resistant Prostate Cancer to Immunotherapy$324,002
P50 · FY2021 · CA · contact PI
Target MIC shedding to revive anti-tumor immunity$49,735
R01 · FY2021 · CA · contact PI
Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer$681,039
R44 · FY2020 · CA · contact PI
Tumor immune and glycan biomarkers for progressive prostate cancer$529,005
R01 · FY2020 · CA · contact PI
Target MIC shedding to revive anti-tumor immunity$361,425
R01 · FY2020 · CA · contact PI
NKG2D superagonist co-stimulation to enhance adaptive immunotherapy of cancer$354,698
R01 · FY2020 · CA · contact PI
Development of a novel class of immunotherapeutic antibody for metastatic prostate cancer$818,940
R44 · FY2019 · CA
Tumor immune and glycan biomarkers for progressive prostate cancer$513,134
R01 · FY2019 · CA · contact PI
Target MIC shedding to revive anti-tumor immunity$350,581
R01 · FY2019 · CA · contact PI
NKG2D superagonist co-stimulation to enhance adaptive immunotherapy of cancer$344,056
R01 · FY2019 · CA · contact PI
Tumor immune and glycan biomarkers for progressive prostate cancer$563,176
R01 · FY2018 · CA · contact PI
NKG2D superagonist co-stimulation to enhance adaptive immunotherapy of cancer$354,698
R01 · FY2018 · CA · contact PI
NKG2D superagonist co-stimulation to enhance adaptive immunotherapy of cancer$354,698
R01 · FY2017 · CA · contact PI
Target MIC shedding to revive anti-tumor immunity$341,981
R01 · FY2017 · CA · contact PI
Optimization of a novel cancer immunotherapeutic antibody for human use$50,000
R41 · FY2017 · CA · contact PI
NKG2D superagonist co-stimulation to enhance adaptive immunotherapy of cancer$341,981
R01 · FY2016 · CA · contact PI
Target MIC shedding to revive anti-tumor immunity$341,981
R01 · FY2016 · CA · contact PI
Optimization of a novel cancer immunotherapeutic antibody for human use$299,994
R41 · FY2016 · CA · contact PI
Targeting MIC shedding to revive host NKG2D-mediated immune response in prostate$323,972
R01 · FY2014 · CA · contact PI
Targeting MIC shedding to revive host NKG2D-mediated immune response in prostate$313,952
R01 · FY2013 · CA · contact PI
Targeting MIC shedding to revive host NKG2D-mediated immune response in prostate$333,992
R01 · FY2012 · CA · contact PI
Targeting MIC shedding to revive host NKG2D-mediated immune response in prostate$353,238
R01 · FY2011 · CA · contact PI
Targeting MIC shedding to revive host NKG2D-mediated immune response in prostate$161,850
R01 · FY2010 · CA · contact PI
Modeling MIC Shedding in Prostate Cancer Progression$149,721
K01 · FY2009 · CA · contact PI
Modeling MIC Shedding in Prostate Cancer Progression$153,306
K01 · FY2008 · CA · contact PI
Modeling MIC Shedding in Prostate Cancer Progression$131,706
K01 · FY2007 · CA · contact PI
Modeling MIC Shedding in Prostate Cancer Progression$131,706
K01 · FY2006 · CA · contact PI
Modeling MIC Shedding in Prostate Cancer Progression$131,706
K01 · FY2005 · CA